Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity

SIMPLE SUMMARY: The standard of care (SoC) for patients with unresectable stage III non-small-cell lung cancer is concurrent chemoradiation followed by durvalumab. Because of co-morbidities, however, the concurrent approach is only amenable for about one-third of patients. While sequential regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Wass, Romana, Hochmair, Maximilian, Kaiser, Bernhard, Grambozov, Brane, Feurstein, Petra, Weiß, Gertraud, Moosbrugger, Raphaela, Sedlmayer, Felix, Lamprecht, Bernd, Studnicka, Michael, Zehentmayr, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265119/
https://www.ncbi.nlm.nih.gov/pubmed/35804997
http://dx.doi.org/10.3390/cancers14133226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265119/
https://www.ncbi.nlm.nih.gov/pubmed/35804997
http://dx.doi.org/10.3390/cancers14133226

Ejemplares similares